{
  "trial_id": "NCT02112630",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Adult (ages 18-75)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Hepatitis C Virus ribonucleic acid (HCV RNA) 1000 IU/mL or greater",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Hepatitis C Virus (HCV) genotype 1",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "End stage renal disease on hemodialysis",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Females of child bearing potential must be using an adequate method of contraception throughout the study and must have a negative pregnancy test prior to the start of treatment.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Intolerance to peg-IFN or ribavirin with prior treatment course.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Prior treatment with protease inhibitor (telaprevir or boceprevir) or experimental protease inhibitor.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Significant cytopenias: Absolute neutrophil count (ANC) < 1000/mm3, OR Hemoglobin (Hgb) <10.5 g/dL, or Platelet count < 50,000/mm3.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Significant laboratory abnormalities: Direct bilirubin > 1.5 x upper limit of normal (ULN).",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "6",
    "trial_id": "NCT02112630",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}